New York, FTC sue 'pharma bro' Shkreli, others over Daraprim price hikes

WASHINGTON (Reuters) - Martin Shkreli, the "pharma bro" in prison for defrauding investors, faces a lawsuit filed by the Federal Trade Commission and New York Attorney General's office for a scheme to preserve his monopoly for the drug Daraprim, which has seen gigantic price increases.The lawsuit accuses a company that Shkreli once ran of buying the rights to Daraprim, which is used to treat toxoplasmosis, and quickly raising the price from $17.50 (13 pounds) per tablet to $750 (571 pounds)..